Salim Rizk, MD
Critical Care Medicine · Towson, MDNPI 1407989601
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Boehringer Ingelheim at 24.9% of the total. Reporting peaked in 2019 at $835 and has fallen 82.6% since, to $145 in 2025.
Across 69 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$333
- GSK$209
- Atricure, Inc.$181
- AstraZeneca$108
- Idorsia Pharmaceuticals US Inc$73
- Sunovion Pharmaceuticals Inc.$62
- plus $371 from 14 others
What the payments were for
- Food & beverage$1,30097%
- Education$373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $333 |
| GSK | 19 | $209 |
| Atricure, Inc. | 4 | $181 |
| AstraZeneca(2 entities) | 6 | $108 |
| Idorsia Pharmaceuticals US Inc | 1 | $73 |
| Sunovion Pharmaceuticals Inc. | 4 | $62 |
| Jazz Pharmaceuticals Inc. | 3 | $57 |
| Resmed Corp | 3 | $49 |
| Genentech USA, Inc. | 2 | $41 |
| Mylan Specialty L.p. | 1 | $32 |
| AbbVie | 2 | $31 |
| Grifols USA, LLC | 2 | $30 |
| United Therapeutics Corporation | 1 | $23 |
| Bayer | 1 | $20 |
| Pulmonx Corporation | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Biomerieux Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,337 in reported general payments places this provider in the 80th percentile of 231 critical care medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $158,138 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $77,691 |
| XolairOmalizumab | 28 | $59,322 |
| Atrovent HfaIpratropium Bromide | 73 | $36,717 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $27,070 |
| Qvar RedihalerBeclomethasone Dipropionate | 19 | $5,669 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $5,089 |
| Fluticasone Propionate HfaFluticasone Propionate | 17 | $4,837 |
| Budesonide | 23 | $3,589 |
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 72 | $1,780 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,684 |
| Acetylcysteine | 12 | $551 |
| Azelastine Hcl | 12 | $404 |
| Montelukast Sodium | 13 | $140 |
| Prednisone | 20 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $333 | $158,13812 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $209 | $104,761113 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $11 | $5,66919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 231 critical care medicine providers in Maryland.
Other critical care medicine in Towson
- Cynthia SorianoTowson$8K
- Lewis RubinsonTowson$5K
- Christopher ChapmanMitchellville$248K
- David Feller KopmanBaltimore$236K
- Elizabeth HuntBaltimore$182K
- Robert BrowningBethesda$73K
- Edward BrittBaltimore$70K
- Lydia Gilbert-McclainBethesda$68K
- Nirav ShahBaltimore$55K
- Steven KellerBaltimore$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.